- •IPNB, a precursor to invasive adenocarcinoma is analogous to pancreatic IPMN, albeit with a higher rate of malignant transformation compared to the latter
- •IPNB's most commonly present as an extrahepatic intraluminal polypoid mass with upstream biliary ductal dilatation, can present as a stricture with plaque like thickening and upstream biliary ductal dilatation and rarely as ductal dilatation without an associated mass
- •IPNB remains a challenging diagnosis as most cases overlap with imaging appearance of Cholangiocarcinoma, hence requiring a multidisciplinary approach for treatment and surveillance
Materials and methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The 2019 WHO classification of tumours of the digestive system.Histopathology. 2020; 76: 182-188
- Uncommon intraluminal tumors of the gallbladder and biliary tract: spectrum of imaging appearances.Radiographics. 2019; 39: 388-412
- Intraductal papillary neoplasm of the bile duct.World J Gastroenterol. 2013; 19: 8595-8604
- Similarity and differences between intraductal tumors of the bile duct.Am J Surg. 2011; 35: 512-521
- Intraductal neoplasm of bile duct: A biliary equivalent of intraductal papillary neoplasm of pancreas.Hepatology. 2012; 56: 1352-1360
- Intraductal papillary neoplasm of the bile duct: clinical, imaging, and pathologic features.AJR Am J Roentgenol. 2018; 211: 67-75
- Clinicopathologic review of 58 patients with biliary papillomatosis.Cancer. 2004; 100: 783-793
- Morphological classification of intraductal papillary neoplasm of the bile duct.Eur Radiol. 2018; 28: 1568-1578
- CT findings of intraductal papillary neoplasm of the bile duct: assessment with multiphase contrast-enhanced examination using multi-detector CT.Clin Radiol. 2012; 67: 224-231
- Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach.J Hepatobiliary Pancreat Sci. 2010; 17: 211-222
- Mucinous cystic neoplasm of the liver or intraductal papillary mucinous neoplasm of the bile duct? A case report and a review of literature.Ann Hepatol. 2018; 17: 519-524
- Clinical and pathological features of intraductal papillary neoplasm of the biliary tract and gallbladder.HPB (Oxford). 2015; 17: 811-818
- Simultaneous liver mucinous cystic and intraductal papillary mucinous neoplasms of the bile duct: a case report.World J Gastroenterol. 2014; 20: 4102-4105
- Cystic lesions of the pancreas: differential diagnosis and cytologic-histologic correlation.Arch Pathol Lab Med. 2019; 144: 47-61
- Clinicopathological characterization of so-called “cholangiocarcinoma with intraductal papillary growth” with respect to “intraductal papillary neoplasm of bile duct (IPNB)”.Int J Clin Exp Pathol. 2014; 7: 3112-3122
- Characterization of intraductal papillary neoplasm of the bile duct with respect to the histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm.Gut Liver. 2019; 13: 617-627
- Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.Cancer. 2010; 116: 3369-3377
- Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses.Radiographics. 2001; (Spec No): S97-S116
- Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings.Radiology. 2011; 260: 148-157
- Intraductal papillary mucinous neoplasm of the biliary tract: a precursor lesion to cholangiocarcinoma.Radiol Case Rep. 2019; 14: 495-500
- Impact of tumor location on postoperative outcome of intraductal papillary neoplasm of the bile duct.World J Surg. 2019; 43: 1313-1322
☆Institutional review board approval was obtained and informed consent waived for this Health Insurance.
☆☆Portability and Accountability Act (HIPAA)-compliant retrospective cohort study.
☆☆☆Jiaqi Shi received partial funding from National Cancer Institute of the National Institutes of Health under Award Number K08CA234222.